Trailing-twelve-month (TTM) revenue is $320.17 Million with a year-over-year growth of +9.46%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-08-31 | $75,711,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-02 |
| Q2 FY2026Period ended 2025-11-30 | $79,433,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-01-06 |
| Q3 FY2026Period ended 2026-02-28 | $78,423,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-02 |
| Q4 FY2026Period ended 2026-05-31 | $86,607,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-14 |
| TTM revenue | $320,174,000 |
Current P/S: $614,612,624 market capitalization ÷ $320,174,000 TTM revenue = 1.92x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:20:15.000Z. Latest revenue period ended 2026-05-31.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-05-31): $86.61M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:20:41.247Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-05-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2026-05-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20182018-05-31 · USD | FY20192019-05-31 · USD | FY20202020-05-31 · USD | FY20212021-05-31 · USD | FY20222022-05-31 · USD | FY20242024-05-31 · USD |
|---|---|---|---|---|---|---|
| Access | $93M | $95M | $94M | N/A | N/A | N/A |
| Endovascular Therapies | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-05-31 · USD | FY20222022-05-31 · USD | FY20232023-05-31 · USD | FY20242024-05-31 · USD | FY20252025-05-31 · USD | FY20262026-05-31 · USD |
|---|---|---|---|---|---|---|
| International | N/A | N/A | N/A | $52M | $42M | N/A |
| Non-US | $14M | $14M | $12M |
$320.17M
$320.17 Million
+9.46%
vs. $292.50M a year ago (TTM)
+1.93%
5 Year compound annual growth rate
1 Year
+9.46%
3 Year
(1.86%)
5 Year
+1.93%
10 Year
(0.99%)
15 Year
+2.66%
20 Year
+7.29%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $320.17M | +$27.68M | +9.46% |
| 2025 | $292.50M | ($11.42M) | (3.76%) |
| 2024 | $303.91M | ($34.84M) | (10.28%) |
| 2023 | $338.75M | +$22.53M | +7.13% |
| 2022 | $316.22M | +$25.21M | +8.66% |
| 2021 |
TTM Growth
+9.46%
3-Year CAGR
(1.86%)
5-Year CAGR
+1.93%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:20:41.247Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $135M |
| N/A |
| N/A |
| Med Device | N/A | N/A | N/A | N/A | $238M | $198M |
|---|
| Med Tech | N/A | N/A | N/A | N/A | $79M | $106M |
|---|
| Oncology Surgery | $49M | N/A | $57M | $55M | N/A | N/A |
|---|
| Peripheral Vascular | $202M | N/A | $113M | N/A | N/A | N/A |
|---|
| N/A |
| $45M |
| UNITED STATES | $121M | $147M | $84M | $251M | $251M | $275M |
|---|
| $291.01M |
| +$26.85M |
| +10.17% |
| 2020 | $264.16M | ($95.33M) | (26.52%) |
| 2019 | $359.48M | +$15.20M | +4.41% |
| 2018 | $344.29M | ($5.36M) | (1.53%) |
| 2017 | $349.64M | ($4.05M) | (1.14%) |
